Evaluating Changes in Patient-Reported Outcomes and Behavior with the Accu-Chek SmartGuide CGM and Predict App in Adults with Insulin-Treated Diabetes
Led by FIDAM RDC · Updated on 2026-10-22
89
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the Accu-Chek SmartGuide continuous glucose monitoring CGM system and its predictive features in adults with type 1 diabetes or insulin-treated type 2 diabetes. The study aims to understand if using the Predict App alongside the CGM system affects fear of hypoglycemia, psychological well-being, sleep quality, confidence in preventing low blood sugar, and diabetes-related distress and empowerment. It also assesses changes in glucose levels and how participants respond to CGM alarms and trend information.
Participants will use the Accu-Chek SmartGuide CGM system for 6 weeks. For the first 2 weeks, they will use the system without the predictive features. Then, they will receive training on the Predict App and use the system with predictive features enabled for the following 4 weeks. This study is conducted remotely with no in-person visits.
During the study, participants will complete online questionnaires after 2 and 6 weeks and answer short questions twice daily using a smartphone app during the first and last 2 weeks. CGM data will be collected continuously to measure glucose ranges, variability, and mean levels. Additionally, a subgroup of 10 participants will be interviewed online about their experiences with the predictive features. The main outcome measured is the change in fear of hypoglycemia over the 4-week period using the Predict App.
CONDITIONS
Brief Title
Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict App
Research Team
D
Dominic Ehrmann, Prof. Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with type 1 diabetes or type 2 diabetes treated with intensified insulin therapy (basal-bolus with self-adjusted bolus doses)
Used continuous glucose monitoring (CGM) without predictive features during the past 3 months
HbA1c less than 10%
Provided informed consent
You will not qualify if you...
Current use of the SmartGuide CGM solution
Use of automated insulin delivery (AID) systems
Current treatment with psychiatric medications
Diabetes diagnosis less than 3 months ago
Current or planned pregnancy
Peripheral neuropathy affecting sleep quality as judged by the participant
Severe complications such as kidney disease or cancer
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Online screening and consent
Initial CGM Use Without Predictive Features
Duration - 2 weeks
Participants use the Accu-Chek SmartGuide CGM system without predictive features to collect baseline data and complete questionnaires and daily surveys.
Twice daily smartphone app surveys and online questionnaires at start and end
CGM Use With Predictive Features
Duration - 4 weeks
Participants use the Accu-Chek SmartGuide CGM system with the Predict App enabled, completing questionnaires and daily ecological momentary assessments.
Twice daily smartphone app surveys and online questionnaires at end
Optional Interview
Duration - After 6 weeks
A subgroup of 10 participants may take part in an online interview to share experiences with the predictive features and provide feedback.
One online interview session
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Early Detection of Type 2 Diabetes and Cardiovascular Risks Using CUORE and FINDRISC Tools in Adults Turning 50 in Marche Region
AI-Assisted Smart Family Doctor for Managing Hypertension, Diabetes, and Dyslipidemia in Adults After Coronary Artery Bypass Graft or Percutaneous Coronary Intervention
Randomized Phase I Study Comparing Bioavailability and Safety of SHR-3167 Injection in Healthy Adults Aged 18 to 55
Pilot Study of a Fruit and Vegetable Prescription Program to Improve Diabetes Management in Adults with Type 2 Diabetes
Evaluating a Digital Tool to Help Clinicians Prescribe Personalized Exercise for Adults with Cardiovascular Disease Risk Factors in a Randomized Crossover Trial
Screening for Pancreatic Cancer in Adults Over 50 with New or Worsening Diabetes Using MRI and Blood Tests
Study Using Near-Infrared Spectroscopy and Optical Coherence Tomography to Evaluate Coronary Vulnerable Plaques in Adults with Diabetes
Study Comparing Standard and Enhanced Get Ready Smartphone Apps to Support Patients After Bariatric Surgery
Evaluating a Culturally Tailored Sleep Hygiene Program to Improve Sleep Health in Urban Latino Middle School Children
Phase I Study of Intraperitoneal Mesothelin-Targeted CAR T-Cell Therapy for Mesothelin-Positive Esophagogastric Adenocarcinoma and Malignant Peritoneal Mesothelioma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Beyond the Trend Arrow: Potential Value of Artificial Intelligence-Supported Glucose Predictions for People with Type 1 Diabetes Using Continuous Glucose Monitoring Systems.
Sufyan Hussain, William Polonsky, Renza Scibilia...